Are there other GLP-1 drugs approved for kidney disease besides Ozempic?
No. Ozempic (semaglutide) is not the only GLP-1 medicine approved to treat kidney-related outcomes. Other GLP-1–based drugs and kidney-indication approvals exist, depending on the specific country and the exact indication (for example, chronic kidney disease vs. diabetic kidney disease vs. cardiovascular risk in people with kidney disease).
What exactly is Ozempic approved for?
Ozempic is approved as a GLP-1 receptor agonist for type 2 diabetes and related uses such as reducing the risk of major cardiovascular events in some people with type 2 diabetes. Kidney “treatment” approvals are not the same as approvals that target kidney outcomes directly, and the exact label matters.
Which GLP-1 medicines might also be used when kidney disease is involved?
Some GLP-1 receptor agonists are used in people with type 2 diabetes who also have chronic kidney disease, but approval status depends on:
- the country’s labeling,
- whether the indication is “kidney disease” (renal indication) versus diabetes plus cardiovascular risk,
- the stage of kidney impairment and whether dose adjustments are allowed.
How to confirm what’s truly “approved for kidney disease” in your location
Check the product label for your country and look for the words “chronic kidney disease,” “diabetic kidney disease,” or “renal outcomes.” Pharmacy and regulatory labeling will distinguish between:
- approvals aimed at diabetes,
- approvals aimed at cardiovascular risk reduction,
- and any specific approvals that mention kidney disease directly.
Common follow-up: Are GLP-1 drugs the main kidney-protective medicines?
In diabetes and chronic kidney disease, the strongest kidney-protective medication categories are usually:
- SGLT2 inhibitors, and
- ACE inhibitors/ARBs (for appropriate patients),
with GLP-1 receptor agonists more often used for glycemic control and cardiovascular risk and potentially kidney benefits in broader clinical contexts.
If you tell me your country, I can be more specific
Approval language changes by regulator. If you share your country (or which regulator’s label you’re looking at) and whether you mean chronic kidney disease or diabetic kidney disease, I can help you pinpoint which GLP-1 drugs are actually approved for that kidney indication where you live.
Sources
No sources were provided in the prompt, so I can’t cite labeling or regulatory documents here.